Analysts Set Apyx Medical Corporation (NASDAQ:APYX) Price Target at $6.60

Apyx Medical Corporation (NASDAQ:APYX) has been assigned a consensus recommendation of “Moderate Buy” from the seven ratings firms that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, four have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $6.60.

Several analysts have recently commented on the stock. HC Wainwright initiated coverage on shares of Apyx Medical in a report on Monday. They issued a “buy” rating and a $7.00 target price for the company. Zacks Research upgraded shares of Apyx Medical to a “hold” rating in a report on Tuesday. Wall Street Zen downgraded shares of Apyx Medical from a “buy” rating to a “hold” rating in a research report on Sunday, April 26th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Apyx Medical in a research report on Wednesday, June 24th.

Apyx Medical Trading Down 1.8%

Shares of Apyx Medical stock opened at $4.34 on Tuesday. The stock has a fifty day simple moving average of $4.23 and a 200 day simple moving average of $3.90. Apyx Medical has a 12-month low of $1.59 and a 12-month high of $5.08. The company has a market capitalization of $181.89 million, a P/E ratio of -19.73 and a beta of 1.37. The company has a current ratio of 5.80, a quick ratio of 4.79 and a debt-to-equity ratio of 2.68.

Apyx Medical (NASDAQ:APYX) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.06. The business had revenue of $12.49 million for the quarter, compared to analysts’ expectations of $10.53 million. Apyx Medical had a negative return on equity of 88.47% and a negative net margin of 16.40%. On average, sell-side analysts anticipate that Apyx Medical will post -0.21 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Apyx Medical

Hedge funds and other institutional investors have recently modified their holdings of the business. Nantahala Capital Management LLC grew its holdings in shares of Apyx Medical by 2.5% in the second quarter. Nantahala Capital Management LLC now owns 3,338,048 shares of the company’s stock valued at $7,511,000 after acquiring an additional 80,000 shares in the last quarter. Osaic Holdings Inc. bought a new stake in Apyx Medical during the second quarter worth $50,000. Vanguard Group Inc. lifted its holdings in Apyx Medical by 3.6% during the third quarter. Vanguard Group Inc. now owns 1,528,947 shares of the company’s stock worth $3,272,000 after acquiring an additional 53,175 shares during the period. Franklin Resources Inc. purchased a new position in Apyx Medical in the third quarter worth $59,000. Finally, Citadel Advisors LLC bought a new position in Apyx Medical in the 3rd quarter valued at $28,000. Hedge funds and other institutional investors own 55.33% of the company’s stock.

Key Headlines Impacting Apyx Medical

Here are the key news stories impacting Apyx Medical this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating on Apyx Medical and a $7.00 price target, suggesting meaningful upside from current levels. Apyx Medical analyst coverage
• Neutral Sentiment: Analyst estimates point to continued, but modest, quarterly losses in 2026 and 2027, indicating the company is still working toward sustained profitability. Apyx Medical analyst coverage
• Neutral Sentiment: Zacks Research upgraded Apyx Medical to Hold, which may reflect a more balanced view of the stock’s near-term risk/reward rather than strong downside or upside conviction. Zacks upgrade

About Apyx Medical

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.